Author(s):
Ahmed Abdullah Elberry, Hoda Rabea, Shireen M. Mohsen, Abdel-Rehim Mourad, Gaafar Kinawy
Email(s):
shireenpharma@gmail.com
DOI:
10.52711/0974-360X.2023.00059 
Address:
Ahmed Abdullah Elberry1, Hoda Rabea2, Shireen M. Mohsen3*, Abdel-Rehim Mourad3, Gaafar Kinawy4
1Clinical Pharmacology Department, Faculty of Medicine, Beni Suef University, Beni Suef, Egypt. Pharmacy Practice Department, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia.
2Clinical Pharmacy Department, Faculty of Pharmacy, Beni Suef University, Beni Suef, Egypt.
3Clinical Pharmacy Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt.
4Obstetrics and Gynecology Department, Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt.
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2023
ABSTRACT:
Objective: The rate of Diabetes in Egypt has significantly increased, exceeding international rates. The International Diabetes Federation (IDF) listed Egypt among the world's top 10 countries in the number of patients with Diabetes. There are two primary subtypes of Diabetes in pregnancy. One of these is pregestational diabetes mellitus (PGDM), which occurs before a woman becomes pregnant. The second is hyperglycemia, which was first detected during pregnancy and should be classified as DM in pregnancy (DIP) or gestational DM according to WHO guidelines (GDM). DIP is a disease that may be diagnosed if typical DM criteria are reached during screening, while GDM is diagnosed when women satisfy at least one of the criteria during a 100g oral glucose tolerance test, according to current guidelines (OGTT). GDM is a condition that affects pregnant women who develop hyperglycemia but do not have a history of Diabetes. Method: This prospective study was conducted on ninety pregnant females with normal menstrual cycles before pregnancy. Patient’s demographics, urine and blood analysis, HbA1c and OGTT at 24 weeks gestation, as well as ultrasonic screening for early prediction of any congenital malformations were assayed. Results: There was a significant difference in terms of Oral glucose tolerance test at week 24 during fasting, Oral glucose tolerance test at week 24 after one hour, Oral glucose tolerance test at week 24 after two hours, Oral glucose tolerance test at week 24 after three hours using 100 gms glucose; p-value <0.05. Conclusion: The results of this study concluded that mothers with PGDM had worse pregnancy outcomes than those with GDM.
Cite this article:
Ahmed Abdullah Elberry, Hoda Rabea, Shireen M. Mohsen, Abdel-Rehim Mourad, Gaafar Kinawy. Comparative Study between Gestational and Chronic diabetic women: Incidence, Predictive Factors and Maternal and Fetal complications. Research Journal of Pharmacy and Technology 2023; 16(1):333-8. doi: 10.52711/0974-360X.2023.00059
Cite(Electronic):
Ahmed Abdullah Elberry, Hoda Rabea, Shireen M. Mohsen, Abdel-Rehim Mourad, Gaafar Kinawy. Comparative Study between Gestational and Chronic diabetic women: Incidence, Predictive Factors and Maternal and Fetal complications. Research Journal of Pharmacy and Technology 2023; 16(1):333-8. doi: 10.52711/0974-360X.2023.00059 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-1-59
REFERENCE:
1. Knowler W, Drews K, Redman L et al. (2018): Changing Glucose Tolerance during Pregnancy— Implications for Diagnosis of Gestational Diabetes Mellitus (GDM). https://diabetes.diabetesjournals. org/content/67/Supplement_1/119-OR
2. Namba B, Namara A, Nyirenda M (2019): Burden, risk factors and maternal and offspring outcomes of gestational diabetes mellitus (GDM) in sub-Saharan Africa (SSA): a systematic review and meta-analysis. BMC Pregnancy and Childbirth, 19 (1): 450-5.
3. Januvia T, Zeitlin J, Egorova N, Balbierz A, Howell EA: The role of obesity in the risk of gestational diabetes among immigrant and U.S.-born women in New York City. Ann Epidemiol 2018;28:242–248.
4. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004; 27 Suppl 1:S88.
5. Viana LV, Gross JL, Azevedo MJ. Dietary intervention in patients with gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials on maternal and newborn outcomes. Diabetes Care 2014; 37:3345.
6. Walkinshaw SA. Dietary regulation for 'gestational diabetes'. Cochrane Database Syst Rev 2000; :CD000070.
7. Singh B. Lohan S. Sandhu PS. Jain A. Mehta SK. Functionalized carbon nanotubes and their promising applications in therapeutics and diagnostics. In Nanobiomaterials in Medical Imaging 2016; 455-478, William Andrew Publishing. https://doi.org/10.1021/nn700040t.
8. Schrader HM, Jovanovic-Peterson L, Bevier WC, Peterson CM. Fasting plasma glucose and glycosylated plasma protein at 24 to 28 weeks of gestation predict Macrosomia in the general obstetric population. Am J Perinatol 1995; 12:247.
9. Scholl TO, Sowers M, Chen X, Lenders C. Maternal glucose concentration influences fetal growth, gestation, and pregnancy complications. Am J Epidemiol 2001; 154:514.
10. Jensen DM, Korsholm L, Ovesen P, et al. Adverse pregnancy outcome in women with mild glucose intolerance: is there a clinically meaningful threshold value for glucose?
a. Acta Obstet Gynecol Scand 2008; 87:59.
11. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358:1991.
12. Pettitt DJ, McKenna S, McLaughlin C, et al. Maternal glucose at 28 weeks of gestation is not associated with obesity in 2-year-old offspring: the Belfast Hyperglycemia and Adverse Pregnancy Outcome (HAPO) family study. Diabetes Care 2010; 33:1219.
13. Schneider SH, Ruderman NB. Exercise and NIDDM. Diabetes Care 1993; 16:54.
14. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol 1989; 161:415.
15. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol 1989;161:415.
16. Barakat R, Pelaez M, Lopez C, et al. Exercise during pregnancy and gestational diabetes-related adverse effects: arandomized controlled trial. Br J Sports Med 2013; 47:630.16.Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010; 33:e147.
17. American Diabetes Association. 13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2018. Diabetes Care 2021; 41:S137.
18. Ballesteros B. Tobias G. Shao L. Pellicer E. Nogués J. Mendoza E. Green ML et al Steam Purification for the Removal of Graphitic Shells Coating Catalytic Particles and the Shortening of Single-Walled Carbon Nanotubes. Small. 2008; 4(9):1501-6.doi.org/10.1021/ja061680u.
19. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression ofretinopathy.TheDiabetesinEarly Pregnancy Study.NationalInstituteofChild Health and Human Development Diabetes in Early Pregnancy Study.DiabetesCare1995;18:631.
20. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucosecontrolonlatecomplicationsoftypeIDiabetes.Lancet1993;341:1306.
21. EarlyworseningofdiabeticretinopathyintheDiabetesControlandComplications Trial. ArchOphthalmol 1998; 116:874.
22. KandaE,MatsudaY,MakinoY,MatsuiH.Riskfactorsassociatedwithaltered fetal growth in patients with pregestational diabetes mellitus. J MaternFetalNeonatalMed2012; 25:1390.
23. Langer O, Levy J, Brustman L, et al. Glycemic control in gestational diabetesmellitus--how tight is tight enough: small for gestational age versus large forgestationalage?AmJObstetGynecol1989;161:646.
24. Carl J, Christensen M, Mathiesen O. Human placental lactogen (hPL) modelforthenormal pregnancy.Placenta1991;12:289.
25. Glueck CJ, Goldenberg N, Pranikoff J, et al. Height, weight, and motor-socialdevelopment during the first 18 months of life in 126 infants born to 109mothers with polycystic ovary syndrome who conceived on and continuedmetforminthroughpregnancy.HumReprod 2004;19:1323.
26. Glueck CJ, Bornovali S, Pranikoff J, et al. Metformin, Preeclampsia, andpregnancy outcomes in women with polycystic ovary syndrome. Diabet Med2004; 21:829.
27. GlueckCJ,GoldenbergN,WangP,etal.Metforminduringpregnancyreduces insulin, insulin resistance, insulin secretion, weight, testosterone anddevelopment of gestational diabetes: prospective longitudinal assessment ofwomenwithpolycysticovarysyndromefrompreconceptionthroughoutpregnancy.HumReprod 2004;19:510.
28. GlueckCJ,PranikoffJ,AregawiD,WangP.PreventionofGestationalDiabetes by metformin plus diet in patients with polycystic ovary syndrome.FertilSteril2008;89:625.
29. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting Diabetes forpregnancy: summary of evidence and consensus recommendations for care.DiabetesCare2008;31:1060.
30. Institute of Medicine and National Research Council. Weight Gain DuringPregnancy: Reexamining the Guidelines, Rasmussen KM, Yaktine AL (Eds),NationalAcademiesPress, Washington,DC2009.
31. Hillier TA,PetulaKL,VescoKK,etal.Excessgestationalweightgain:modifyingfetalmacrosomiariskassociatedwithmaternalglucose.ObstetGynecol2008;112:1007.
32. Scifres CM, Feghali MN, Althouse AD, et al. Effect of excess gestationalweight gain on pregnancy outcomes in women with type 1 diabetes. ObstetGynecol2014;123:1295.
33. Stecher AL, Parellada CB, Ringholm L, et al. Higher gestational weight gain isassociatedwithincreasingoffspringbirthweightindependentofmaternalglycemiccontrolinwomenwithtype1diabetes.DiabetesCare2014;37:2677.
34. Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles andrecommendationsfor the treatmentandprevention of diabetes andrelatedcomplications. DiabetesCare2003; 26 Suppl1:S51.
35. Harris JA, Benedict FG. A Biometric Study of Human Basal Metabolism. ProcNatl AcadSci U S A1918; 4:370.
36. Mifflin MD, St Jeor ST, Hill LA, et al. A new predictive equation for restingenergyexpenditurein healthy individuals.Am JClin Nutr1990; 51:241.
37. BertorelliAM.Nutritionalmanagement.In:DiabetesComplicatingPregnancy, 2nd ed, Brown FM, Hare JW (Eds), Wiley-Liss, New York 1995.p.88.
38. MestmanJH.OutcomeofDiabetesscreeninginpregnancyandperinatalmorbidity in infants of mothers with mild impairment in glucose tolerance.DiabetesCare1980;3:447.
39. American Diabetes Association. 3. Foundations of Care and ComprehensiveMedicalEvaluation.DiabetesCare2016; 39Suppl 1:S23.
40. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrinesocietyclinicalpractice guideline.JClinEndocrinolMetab2013;98:4227.
41. Wilson RD, Genetics Committee, Wilson RD, et al. Pre-conception Folic Acidand Multivitamin Supplementation for the Primary and Secondary Preventionof Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies.JObstet GynaecolCan 2015; 37:534.
42. Jovanovic L, Knopp RH, Brown Z, et al. Declining insulin requirement in thelatefirsttrimester ofdiabetic pregnancy.DiabetesCare 2001;24:1130.
43. SteelJM,JohnstoneFD,HumeR,MaoJH.InsulinrequirementsduringpregnancyinwomenwithtypeIDiabetes.ObstetGynecol1994;83:253.
44. García-Patterson A, Gich I, Amini SB, et al. Insulin requirements throughoutpregnancy in women with type 1 diabetes mellitus: three changes of direction.Diabetologia2010;53:446.
45. HirschIB.Insulin analogues.NEnglJ Med2005;352:174.
46. Wyatt JW, Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring ofmothers with diabetes treated with insulin lispro during pregnancy.DiabetMed2005; 22:803.
47. Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1diabetes pregnancy: a randomized study comparing insulin aspart with humaninsulinin 322subjects.AmJObstet Gynecol2008; 198:186.e1.